Transaction DateRecipientSharesTypePriceValue
6th January 2021Capital, Llc Armistice0Open or private purchase$0.00
6th January 2021Capital, Llc Armistice1,531,101Open or private purchase$5.23$8,000,002.73
4th December 2020Capital, Llc Armistice0Open or private purchase$0.00
4th December 2020Capital, Llc Armistice5,400Open or private purchase$4.13$22,302.00
3rd December 2020Capital, Llc Armistice0Open or private purchase$0.00
3rd December 2020Capital, Llc Armistice20,000Open or private purchase$2.44$48,800.00
2nd December 2020Capital, Llc Armistice1,000Open or private purchase$4.31$4,310.00
2nd December 2020Capital, Llc Armistice0Open or private purchase$0.00
25th November 2020Capital, Llc Armistice0Open or private purchase$0.00
25th November 2020Capital, Llc Armistice15,000Open or private purchase$2.39$35,850.00
Amag Pharmaceuticals
Amag Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.


AMAG Pharmaceuticals, Inc. focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.


Ticker: AMAG
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 792977
Employees: 440
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $99 M (-12%)
Inventory, Net: $30 M (0%)
Assets, Current: $264 M (-16%)
Property, Plant and Equipment, Net: $3 M (0%)
Assets: $716 M (-9%)
Accounts Payable, Current: $13 M (-52%)
Accrued Liabilities, Current: $145 M (0%)
Liabilities, Current: $161 M (-24%)
Long-term Debt, Excluding Current Maturities: $285 M (2%)
Other Liabilities, Noncurrent: $828 Th (830%)
Liabilities: $466 M (-8%)
Common Stock, Value, Issued: $344 Th (1%)
Common Stock, Shares, Issued: $34 M (1%)
Additional Paid in Capital, Common Stock: $1 B (0%)
Retained Earnings (Accumulated Deficit): $1 B (3%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $3 M (-8%)
Stockholders' Equity (Parent): $249 M (0%)
Liabilities and Equity: $716 M (-9%)
Revenue: $53 M (-57%)
Cost of Revenue: $18 M (-57%)
Restructuring Charges: $8 M (0%)
Operating Income/Loss: $7 M (-71%)
Other Income, net: $6 M (-42%)
Provision for income taxes: $160 Th (0%)